Xeomin 100 Units, produced by Merz Company, is an FDA-approved medication akin to Botox and Dysport. It is the first anti-wrinkle injection proven through clinical trials, purified to eliminate unnecessary proteins. Xeomin is primarily used to temporarily reduce the appearance of moderate to severe glabellar lines in adults with corrugator and/or procerus muscle activity.

The active ingredient, botulinum toxin type A, can be injected into glands to manage chronic drooling or into muscles to treat conditions such as upper limb spasticity, cervical dystonia, blepharospasm, and severe frown lines between the eyebrows in adults.

Possible side effects include muscle weakness, double or blurred vision, drooping eyelids, hoarseness, difficulty speaking clearly, loss of bladder control, and challenges with breathing or swallowing.

After a Xeomin 100 Units injection, patients should avoid water contact with the face for an hour, refrain from anti-inflammatory medications for a week, and steer clear of facial massages, hot compresses, and certain foods for a month. Results usually last between 8 to 14 months, with visible effects appearing about a month after the procedure.

One key benefit of Xeomin is its protein-free formula, reducing the likelihood of antibody development, and it can be stored at room temperature for up to three years.